---
title: "Zhejiang ALK received the \"Drug Registration Certificate\" for Amlodipine Besylate Tablets from the U.S"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260856536.md"
description: "Zhejiang ALK Pharmaceutical Co., Ltd. recently obtained the \"Drug Registration Certificate\" for Amlodipine Besylate Tablets issued by the National Medical Products Administration. This medication is used for the treatment of adult primary hypertension, with specifications of 40mg and 80mg, and the approval number is valid until September 29, 2030. This approval is considered equivalent to passing the consistency evaluation, which will enrich the company's product pipeline. However, due to the particularity of the pharmaceutical industry, drug sales are influenced by policy and market factors, and the specific sales situation is uncertain. The company reminds investors to pay attention to risks"
datetime: "2025-10-13T08:40:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260856536.md)
  - [en](https://longbridge.com/en/news/260856536.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260856536.md)
generator: "portal-rs"
---

# Zhejiang ALK received the "Drug Registration Certificate" for Amlodipine Besylate Tablets from the U.S

Recently, Zhejiang ALK Pharmaceuticals Co., Ltd. received the "Drug Registration Certificate" for Measartan Potassium Tablets issued by the National Medical Products Administration. The generic name of this drug is Measartan Potassium Tablets, with main ingredient Measartan Potassium, available in two specifications: 40mg and 80mg. The approval number is valid until September 29, 2030. Measartan Potassium Tablets can be used to treat primary hypertension in adults, and the company received the acceptance notice in 2024. This approval is considered equivalent to passing the consistency evaluation, which will enrich the company's product pipeline. However, due to the particularity of the pharmaceutical industry, drug sales are affected by policies, market conditions, and other factors, making the specific sales situation uncertain. The company reminds investors to pay attention to risks

### Related Stocks

- [002940.CN](https://longbridge.com/en/quote/002940.CN.md)

## Related News & Research

- [Zhejiang Shibao Wins Shareholder Backing for Targeted A-Share Issuance](https://longbridge.com/en/news/299068227.md)
- [Hear why Neuralink co-founder Max Hodak says the screen era is ending at TechCrunch Disrupt 2026](https://longbridge.com/en/news/299209093.md)
- [Eirion Therapeutics to Present Promising First-in-Human ET-02 Data at the Third BCN Hair Meeting](https://longbridge.com/en/news/299187883.md)
- [IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance](https://longbridge.com/en/news/299162485.md)
- [Definium's LSD-based drug lowers anxiety in second successful late-stage study](https://longbridge.com/en/news/298906879.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**